×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NTLA – intellia therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NTLA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/28
05:49 pm
ntla
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold [Yahoo! Finance]
Low
Report
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold [Yahoo! Finance]
1/28
10:59 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) was given a new $25.00 price target on by analysts at KeyCorp.
Low
Report
Intellia Therapeutics (NASDAQ:NTLA) was given a new $25.00 price target on by analysts at KeyCorp.
1/28
09:52 am
ntla
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? [Yahoo! Finance]
Low
Report
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? [Yahoo! Finance]
1/28
08:05 am
ntla
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine
Medium
Report
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine
1/28
07:19 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/27
03:02 pm
ntla
Intellia Therapeutics (NASDAQ:NTLA) was given a new $7.00 price target on by analysts at Robert W. Baird.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) was given a new $7.00 price target on by analysts at Robert W. Baird.
1/27
12:28 pm
ntla
FDA lifts hold on an Intellia CRISPR drug trial [Yahoo! Finance]
Low
Report
FDA lifts hold on an Intellia CRISPR drug trial [Yahoo! Finance]
1/27
08:33 am
ntla
US FDA lifts clinical hold on Intellia's nerve disease trial [Yahoo! Finance]
High
Report
US FDA lifts clinical hold on Intellia's nerve disease trial [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
04:00 pm
ntla
intellia therapeutics, inc.
BEAT
Report
-22.7%
intellia therapeutics, inc.
8/7/2025
07:30 am
ntla
intellia therapeutics, inc.
BEAT
Report
-1.7%
intellia therapeutics, inc.
5/8/2025
07:30 am
ntla
intellia therapeutics, inc.
BEAT
Report
9.5%
intellia therapeutics, inc.
2/27/2025
07:30 am
ntla
intellia therapeutics, inc.
BEAT
Report
-4.7%
intellia therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/30
02:17 pm
ntla
Form SCHEDULE 13G/A Intellia Therapeutics, Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Intellia Therapeutics, Filed by: VANGUARD GROUP INC
1/27
08:19 am
ntla
Form 8-K Intellia Therapeutics, For: Jan 27
Medium
Report
Form 8-K Intellia Therapeutics, For: Jan 27
1/9
08:07 am
ntla
Form 8-K Intellia Therapeutics, For: Jan 09
Low
Report
Form 8-K Intellia Therapeutics, For: Jan 09
1/7
04:06 pm
ntla
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: LEONARD JOHN M
Low
Report
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: LEONARD JOHN M
1/7
04:05 pm
ntla
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Lebwohl David
Medium
Report
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Lebwohl David
1/7
04:05 pm
ntla
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Schultes Birgit C
Low
Report
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Schultes Birgit C
1/7
04:05 pm
ntla
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: BASTA JAMES
Low
Report
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: BASTA JAMES
1/7
04:05 pm
ntla
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Cohen Fred E
Low
Report
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: Cohen Fred E
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/27
Intellia Therapeutics, Inc. (NTLA) Q4 2019 Earnings Call Transcript [The Motley Fool]
17.1%
10/31 Intellia Therapeutics, Inc. (NTLA) Q3 2019 Earnings Call Transcript [The Motley Fool] 9.0%
2/10 Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference 7.6%
11/23 More CRISPR Stock Catalysts Ahead [The Motley Fool] 6.3%
4/22 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.3%
6/7 Form EFFECT Intellia Therapeutics, 5.6%
2/5 Here's Why CRISPR Stocks Fell in January [The Motley Fool] 5.0%
10/31 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus -0.610 ActVsEst 0.120 - Beat 5.0%
3/26 Form 8-K Intellia Therapeutics, For: Mar 26 4.2%
7/8 Intellia +1% after Baird start at Outperform [Seeking Alpha] 4.2%
10/31 Intellia Therapeutics, Inc. (NTLA) Q3 2019 Earnings Call Transcript [The Motley Fool] 9.0%
2/10 Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference 7.6%
11/23 More CRISPR Stock Catalysts Ahead [The Motley Fool] 6.3%
4/22 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.3%
6/7 Form EFFECT Intellia Therapeutics, 5.6%
2/5 Here's Why CRISPR Stocks Fell in January [The Motley Fool] 5.0%
10/31 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus -0.610 ActVsEst 0.120 - Beat 5.0%
3/26 Form 8-K Intellia Therapeutics, For: Mar 26 4.2%
7/8 Intellia +1% after Baird start at Outperform [Seeking Alpha] 4.2%
TOP News Decliners
3/13
Form 8-K Intellia Therapeutics, For: Mar 12
-17.6%
6/10 Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Roth Capital. They set a "neutral" rating and a $16.00 price target on the stock. -10.3%
4/1 Intellia Therapeutics Inc (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $57.50 price target on the stock. -8.8%
8/26 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.2%
4/28 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. -7.8%
9/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was given a new $57.50 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.7%
5/7 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
4/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.6%
4/21 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -7.5%
2/14 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. -7.3%
6/10 Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Roth Capital. They set a "neutral" rating and a $16.00 price target on the stock. -10.3%
4/1 Intellia Therapeutics Inc (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $57.50 price target on the stock. -8.8%
8/26 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.2%
4/28 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. -7.8%
9/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was given a new $57.50 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.7%
5/7 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
4/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.6%
4/21 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -7.5%
2/14 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. -7.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: